BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference


BiomX Contacts

Investor Relations:

LifeSci Advisors, LLC

John Mullaly


[email protected]

BiomX, Inc.

Anat Primovich

Corporate Project Manager

+972 (50) 697-7228

[email protected]

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.


H.C Wainwright Global Investment Conference – September 12-14, 2022



Date & Time:

Monday, September 12, 7:00 AM EST (Available on Demand)


Jonathan Solomon

Conference registration:


Webcasts of presentations will also be accessible through the Investors section of the Company’s website at Following the events, the webcasts will be archived on the BiomX website.

About BiomX Inc.

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.